To use innovative strategies such as multiomics (transcriptomics and epigenomics to metabolomics) and innovative bioinformatic approaches to target prediction by network analysis. The innovative multidisciplinary approach will identify novel therapeutic targets for cardioprotection on the mitochondrial, cellular and organ level.

Combination therapies to targeting different therapeutic targets both within and outside the cardiomyocyte is an innovative approach to cardioprotection.

The mechanisms through which co-morbidities and co-medications confound cardioprotection are not known and will be systematically investigate here for the first time. Understanding these mechanisms may provide new insights into the cardioprotective signalling pathway. The COST Action will identify the most important co-morbidities and co-medications to target in pre-clinical and clinical cardioprotection studies.

There currently exists no European Network of Research Centres jointly investigating new cardioprotective therapies in the laboratory or clinical setting. The ECC will allow multi-centre testing of new cardioprotective therapies to screen promising therapies and identify those that are truly effective in relevant experimental models and, thus, most likely to be effective in patients.